SCHEMBL8172437

SCHEMBL8172437

CC(=O)OCC1CN(C(C)=O)CC(O)C1OC(C)=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 3/20 0.36
CHRNA3 P32297 3/20 0.36
CHRNA4 P43681 3/20 0.36
CHRNB3 Q05901 1/20 0.36
CHRNA6 Q15825 1/20 0.36
CHRNB4 P30926 2/20 0.35
THRB P10828 2/20 0.33
PDK1 Q15118 1/20 0.33
CHRNA7 P36544 1/20 0.33
CYP2D6 P10635 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CA12 O43570 7/20 0.33
CA1 P00915 7/20 0.33
CA2 P00918 7/20 0.33
CA9 Q16790 7/20 0.33
LMNA P02545 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
HIF1A Q16665 1/20 0.33
TSHR P16473 1/20 0.33
NR3C1 P04150 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17698140 0.76 PDK1 (0.37) PDK1HSD17B10LMNA
SCHEMBL17698142 0.76 PDK1 (0.37) PDK1HSD17B10LMNA
SCHEMBL17698141 0.76 PDK1 (0.37) PDK1HSD17B10LMNA
SCHEMBL15119944 0.71 CHRNB2 (0.42) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL15177081 0.71 CHRNB2 (0.42) CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6
SCHEMBL14500640 0.70 THRB (0.43) THRBCYP2D6HSD17B10CA12CA1
SCHEMBL22522050 0.69 CA12 (0.41) THRBCYP2D6HSD17B10CA12CA1
SCHEMBL16217801 0.69 LMNA (0.41) THRBCYP2D6HSD17B10CA12CA1
SCHEMBL20068296 0.68 CA12 (0.40) THRBCYP2D6HSD17B10CA12CA1
SCHEMBL14490117 0.68 NR3C1 (0.41) THRBCYP2D6HSD17B10CA12CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6046214-A USEFUL IN TREATMENT AND/OR PREVENTION OF DIABETES, AND ESPECIALLY NON-INSULIN DEPENDENT DIABETES (NIDDM OR TYPE 2 DIABETES) INCLUDING OVERNIGHT OR MEAL TREATMENT AND TREATMENT OR PREVENTION OF LONGTERM COMPLICATIONS, SUCH AS RETINOPATHY NOVO NORDISK A/S (DK) 2000-04-04 US disclosed
EP-0983239-A1 NOVEL HETEROCYCLIC COMPOUNDS NOVO NORDISK A/S (DK) 2000-03-08 EP disclosed
WO-1998050359-A1 NOVEL HETEROCYCLIC COMPOUNDS NOVO NORDISK A/S (DK) 1998-11-12 WO disclosed